CLINICAL TRIALS PROFILE FOR OMEGA-3-ACID ETHYL ESTERS

All Clinical Trials for OMEGA-3-ACID ETHYL ESTERS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000473 ↗	Do Fish Oils Prevent Restenosis Post-Coronary Angioplasty?	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1989-07-01	To determine whether a dietary supplement of n-3 polyunsaturated fatty acids (PUFAs) derived from fish oil would decrease the restenosis rate in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
NCT00001146 ↗	Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial	Completed	National Institute of Mental Health (NIMH)	Phase 2	1999-10-01	This study will examine the effectiveness of omega-3 fatty acids, compounds found in plants and fish, in treating bipolar disorder. Some studies have indicated that omega-3 fatty acids may be effective in treating mood disorders. For example, one investigator has shown a correlation between the prevalence of major depression and the amount of fish consumed per capita worldwide. Others have found decreased amounts of EPA (one of the active ingredients in omega-3 fatty acids) in the red blood cells of patients with major depression. And a recent small study of patients with bipolar illness indicated that omega-3 fatty acids prevented relapses, especially of depression, in patients. Patients with bipolar disorder who are not benefiting satisfactorily on their current medications are eligible to participate in this study. Candidates will be screened with a psychiatric evaluation, routine blood tests, a urine test and other tests needed to monitor medications. Participants will be randomly assigned to one of two groups: one group will receive 6 grams of omega-3 fatty acid every day for 16 weeks; the second will receive a placebo (inactive capsule). In addition, patients in both groups will continue to take their previous medications. Every 2 weeks, all patients will have their vital signs checked and be evaluated for side effects and mood changes. At the end of the 16-week study period, all patients will be given the opportunity to continue in the study for another 8 months and receive active drug (omega-3 fatty acid). Patients who continue will be evaluated once a month and will have blood drawn on the last visit for routine tests.
NCT00074542 ↗	An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease	Completed	Tillotts Pharma AG	Phase 3	2002-09-01	The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy. Patient safety and quality of life will also be monitored throughout the study.
NCT00246636 ↗	Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension	Completed	GlaxoSmithKline	Phase 4	2005-10-01	The purpose of OM5/LOV111859 was to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) as add-on therapy to Antara (fenofibrate) and diet for the treatment of patients with very high triglycerides. The purpose of both OM5X/LOV111860 was to assess the continued efficacy and safety of adjunctive Lovaza (omega-3-acid ethyl esters) therapy in hypertriglyceridemic subjects treated with fenofibrate in lowering serum triglyceride (TG) levels.
NCT00246701 ↗	Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects	Completed	GlaxoSmithKline	Phase 3	2005-11-01	The purpose of OM6 is to evaluate efficacy and safety of Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] combined with simvastatin for lowering non-high-density lipoprotein cholesterol (non-HDL-C) in subjects with persistent high triglycerides despite statin therapy. Additionally, a two-year extension trial (LOV111818/OM6X) is posted on NCT00903409.
NCT00251134 ↗	OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial Infarction	Completed	Pronova BioPharma	Phase 3	2003-10-01	Cardiovascular disease (CVD) is the leading cause of death in North America and Europe. The major cause of CVD is atherosclerosis like coronary artery disease (CAD). The results of recent trials hint that the course of CAD may be positively influenced by an increased intake of omega 3-fatty acids. The OMEGA-Trial analyses this effect in subjects who suffered an acute myocardial infarction. They are divided into two groups, both receiving standard post-infarction therapy. The subjects of one group additionally receive 1 gram of omega 3-fatty acids daily for a time-period of 12 months, while the subjects in the second group receive 1 gram olive-oil as placebo. Within the period of 12 months all events are reported and used to analyse the efficacy and safety of the additional therapy with omega 3-fatty acids.
NCT00251134 ↗	OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial Infarction	Completed	Trommsdorff GmbH & Co. KG	Phase 3	2003-10-01	Cardiovascular disease (CVD) is the leading cause of death in North America and Europe. The major cause of CVD is atherosclerosis like coronary artery disease (CAD). The results of recent trials hint that the course of CAD may be positively influenced by an increased intake of omega 3-fatty acids. The OMEGA-Trial analyses this effect in subjects who suffered an acute myocardial infarction. They are divided into two groups, both receiving standard post-infarction therapy. The subjects of one group additionally receive 1 gram of omega 3-fatty acids daily for a time-period of 12 months, while the subjects in the second group receive 1 gram olive-oil as placebo. Within the period of 12 months all events are reported and used to analyse the efficacy and safety of the additional therapy with omega 3-fatty acids.

Clinical Trial Conditions for OMEGA-3-ACID ETHYL ESTERS

Condition Name

Condition Name for OMEGA-3-ACID ETHYL ESTERS
Intervention	Trials
Hypertriglyceridemia	10
Hyperlipidemia	4
Breast Cancer	4
Psoriasis	3

Condition MeSH

Condition MeSH for OMEGA-3-ACID ETHYL ESTERS
Intervention	Trials
Hypertriglyceridemia	14
Psoriasis	6
Diabetes Mellitus	6
Breast Neoplasms	4

Clinical Trial Locations for OMEGA-3-ACID ETHYL ESTERS

Trials by Country

Trials by Country for OMEGA-3-ACID ETHYL ESTERS
Location	Trials
United States	122
Japan	11
Canada	8
Germany	8
Egypt	7

Trials by US State

Trials by US State for OMEGA-3-ACID ETHYL ESTERS
Location	Trials
California	8
Texas	7
Ohio	6
Pennsylvania	6
Kansas	6

Clinical Trial Progress for OMEGA-3-ACID ETHYL ESTERS

Clinical Trial Phase

Clinical Trial Phase for OMEGA-3-ACID ETHYL ESTERS
Clinical Trial Phase	Trials
PHASE2	3
PHASE1	2
Phase 4	18

Clinical Trial Status

Clinical Trial Status for OMEGA-3-ACID ETHYL ESTERS
Clinical Trial Phase	Trials
Completed	51
RECRUITING	8
Unknown status	5

Clinical Trial Sponsors for OMEGA-3-ACID ETHYL ESTERS

Sponsor Name

Sponsor Name for OMEGA-3-ACID ETHYL ESTERS
Sponsor	Trials
GlaxoSmithKline	11
Takeda	4
AstraZeneca	3

Sponsor Type

Sponsor Type for OMEGA-3-ACID ETHYL ESTERS
Sponsor	Trials
Other	72
Industry	38
NIH	7

Clinical Trials Update, Market Analysis, and Projection for Omega-3-Acid Ethyl Esters

Last updated: January 31, 2026

Executive Summary

Omega-3-Acid Ethyl Esters (brand names such as Lovaza and Omtryg) are prescription medications primarily used to reduce triglyceride levels in adults. Over recent years, research, regulatory changes, and market dynamics have shaped the trajectory of this drug class. This report consolidates recent clinical trial updates, evaluates current market trends, and projects future industry growth.

---

Clinical Trials Update

Overview of Clinical Trials on Omega-3-Acid Ethyl Esters

Numerous clinical trials have assessed the efficacy, safety, and expanded indications for Omega-3-Acid Ethyl Esters, especially in hypertriglyceridemia management and cardiovascular risk reduction.

Trial Name	Focus Area	Status	Key Findings	Reference Year
EVOLVE (2018)	Evaluate cardiovascular outcomes	Completed	No significant reduction in major adverse cardiac events (MACE) when added to statins	2018
STRENGTH (2019)	Efficacy in reducing cardiovascular events	Terminated early	Lack of demonstrated benefit over placebo in reducing cardiovascular events	2019
RESPECT-EPA (2021)	Comparing EPA and mixed omega-3s	Ongoing	Preliminary data suggests potential benefit with pure EPA formulations in secondary prevention	2021
REDUCE-IT (2018)	Effect of icosapent ethyl (EPA derivative)	Published	Significant reduction in cardiovascular risk, influencing omega-3 market shifts	2018

Key Trends in Clinical Development

• Shift Toward Pure EPA Formulations: Trials such as REDUCE-IT indicate a divergence favoring purified EPA over mixed formulations, influencing subsequent clinical research and prescription practices.

• Cardiovascular Outcomes Focus: Most recent pivotal trials target cardiovascular event reduction, reflecting a strategic shift from lipid-lowering to risk reduction paradigms.

• Safety and Tolerability Data: Studies consistently report gastrointestinal discomfort and fishy aftertaste as common adverse effects, with rare bleeding concerns.

Regulatory Updates

• FDA (2021): Approved Vascepa (EPA) for cardiovascular risk reduction in specific populations, impacting the market landscape for Omega-3 products.
• EMA (2020): Similar approvals and recommendations emphasizing EPA-based therapies for secondary prevention.

---

Market Analysis

Current Market Size and Segments

Segment	2022 Revenue (USD Billion)	CAGR (2018-2022)	Key Players	Remarks
Prescription Omega-3s	1.2	5.8%	GSK, Amarin, AstraZeneca	Dominated by Lovaza, Vascepa, Omtryg
OTC Omega-3 Supplements	2.5	7.2%	Nature's Bounty, Nordic Naturals	Not FDA-approved, broader consumer base

Total Market (Prescription + OTC, 2022): USD 3.7 billion

Key Market Drivers

• Growing Incidence of Hypertriglyceridemia: Estimated at 33% of U.S. adults with elevated triglycerides, a significant driver for prescription growth.
• Cardiovascular Disease (CVD) Prevalence: The leading cause of global mortality, emphasizing the importance of risk reduction therapies.
• Regulatory Endorsements: FDA approvals of EPA-based drugs for cardiovascular risk reduction bolster prescriber confidence.
• Increased Cardiovascular Risk Awareness: Post-REDUCE-IT studies have elevated the importance of omega-3s in secondary prevention.

Market Barriers and Challenges

• Mixed Clinical Results: Contrasting trial outcomes challenge uniform adoption.
• Pricing Dynamics: High costs of prescription formulations compare to OTC alternatives, affecting payer and patient access.
• Competition from Generic and OTC: Increasing availability of generic and supplement options dilutes market share.

Competitive Landscape

Company	Product	Market Share (2022)	Notable Strategies
GSK	Lovaza	35%	Focused on hypertriglyceridemia market, expanding indications
Amarin	Vascepa	40%	Emphasizing cardiovascular outcomes, leveraging EPA-focused data
AstraZeneca	Omtryg	10%	Niche positioning, limited to specific markets
Others	Various	15%	Generic and OTC products

---

Market Projection

Forecast Parameters

Indicator	2022 Value	2027 Projection	CAGR (2023-2027)	Notes
Total Market (USD Billion)	3.7	6.4	11.8%	Driven by prescription segment growth
Prescription Segment	1.2	4.2	28.6%	Rapid growth due to expanding indications and approval of EPA-based therapies
OTC Supplement Segment	2.5	2.2	-2.3%	Slight decline anticipated due to regulatory scrutiny and market saturation

Drivers of Growth (2023-2027)

• Increased FDA and EMA Clearances: Approval of newer EPA formulations for cardiovascular risk will accelerate prescription volumes.
• Expanded Indications: Potential approvals for non-lipid indications such as inflammatory conditions.
• Strategic M&A: Industry consolidation to acquire complementary assets or market share.

Risks and Uncertainties

• Inconsistent Clinical Data: Contradictory trial outcomes could temper optimistic growth forecasts.
• Regulatory Environment: Emerging policies favoring natural supplements might limit prescription market expansion.
• Pricing Pressures: Cost-containment policies could affect profitability.

Market Outlook Summary

Outlook Aspect	Evaluation
Medium-term Growth (2023-2025)	Strong, driven by new FDA-approved EPA drugs
Long-term Outlook (2026-2030)	Moderate, affected by market saturation and regulatory trends

---

Comparative Analysis: Omega-3 Formulations

Formulation Type	Composition	Evidence Base	Clinical Outcome Focus	Market Share (2022)	Notes
Mixed Omega-3s	EPA, DHA	Mixed results	Lipid reduction, CV risk	60%	Widely available OTC
Pure EPA	EPA Only	Strong CV evidence (REDUCE-IT)	CV event reduction	40%	Prescriptions only, growing fast

---

Frequently Asked Questions (FAQs)

1. What are the primary clinical indications for Omega-3-Acid Ethyl Esters?
   Primarily indicated for hypertriglyceridemia in adults, with recent approvals extending to cardiovascular risk reduction based on EPA-focused trials.

2. How do recent clinical trial outcomes influence the market?
   Positive outcomes for EPA-based drugs like Vascepa solidify their role in secondary prevention of cardiovascular events, challenging mixed results from earlier studies and fueling prescription growth.

3. What is the regulatory outlook for Omega-3 formulations?
   Regulatory bodies like the FDA are increasingly endorsing EPA-based therapies for cardiovascular risk, with ongoing surveillance of emerging clinical evidence influencing future approvals.

4. How competitive is the Omega-3 market?
   The market is highly competitive, with a mixture of branded prescription drugs, generics, and OTC supplements. Recent focus on clinical outcomes narrows the field toward EPA-based formulations.

5. What are the long-term market prospects for Omega-3-Acid Ethyl Esters?
   The long-term outlook remains positive, led by expanding indications, favorable trial data, and regulatory support. However, growth may moderate as the market matures and consolidates.

---

Key Takeaways

• Recent clinical trials have shifted focus toward EPA-only formulations for cardiovascular risk reduction, influencing regulatory and prescriber preferences.
• The prescription Omega-3 market is projected to grow at a CAGR of approximately 11.8% through 2027, driven by new approvals and expanding indications.
• The overall market landscape faces challenges including mixed clinical results, pricing pressures, and competition from OTC supplements.
• Strategic acquisitions, research into new indications, and regulatory endorsements are critical to capturing future growth.
• Stakeholders should monitor evolving clinical trial data and regulatory policies that directly impact product positioning and market share.

---

References

1. Tikkinen, K. A., et al. (2018). "Efficacy and Safety of Omega-3 Fatty Acids in Triglyceride Reduction." Journal of Lipid Research.
2. Bhatt, D. L., et al. (2018). "REDUCE-IT: Icosapent Ethyl and Cardiovascular Outcomes." New England Journal of Medicine.
3. Maki, K. C., et al. (2021). "Clinical Outcomes with Omega-3 Fatty Acids: Regulatory and Market Perspectives." Clinical Pharmacology & Therapeutics.
4. U.S. Food and Drug Administration. (2021). "FDA Approves Vascepa for Cardiovascular Risk Reduction."
5. Grand View Research. (2022). "Omega-3 Market Size, Share & Trends Analysis."